Onyx Pharmaceuticals Inc.
2100 Powell Street
Emeryville,
CA 94608
United States - Map
Phone: 510-597-6500
Fax: 510-597-6600
Web Site: http://www.onyx-pharm.com
| Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. The company is also conducting various ongoing trials on Nexavar for conditions, such as non-small cell lung cancer, melanoma, breast cancer, and other cancers. It also develops ONX 0801, an oncology compound in preclinical development stage, under a development and license agreement with BTG International Limited. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells. Onyx Pharmaceuticals was founded in 1992 and is headquartered in Emeryville, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. N. Anthony Coles M.D. M.P.H., 49
Chief Exec. Officer, Pres |
$
1.30M | N/A | Ms. Laura A. Brege , 52
Chief Operating Officer and Exec. VP |
$
612.00K |
$
1.15M | Ms. Judy Batlin , 56
VP of Organizational Learning Devel. & HR |
$
400.00K | N/A | Dr. Juergen Lasowski Ph.D., 52
Sr. VP of Corp. Devel. |
$
355.00K | N/A | Mr. Matthew K. Fust , 45
Chief Financial Officer, Principal Accounting Officer and Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
